Tourmaline Bio Inc
Company Profile
Business description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Contact
27 West 24th Street
Suite 702
New YorkNY10010
USAT: +1 646 481-9832
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,831.50 | 53.60 | 0.61% |
CAC 40 | 7,878.46 | 111.75 | 1.44% |
DAX 40 | 24,549.56 | 342.65 | 1.42% |
Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
FTSE 100 | 8,867.02 | 12.84 | 0.15% |
HKSE | 23,914.79 | 22.47 | 0.09% |
NASDAQ | 20,611.34 | 192.87 | 0.94% |
Nikkei 225 | 39,616.80 | 204.48 | -0.51% |
NZX 50 Index | 12,736.69 | 31.92 | -0.25% |
S&P 500 | 6,263.26 | 37.74 | 0.61% |
S&P/ASX 200 | 8,593.70 | 55.10 | 0.65% |
SSE Composite Index | 3,505.58 | 12.53 | 0.36% |